Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Cilomilast (SB-207499)
Cat No.
CEI-0240
Description
LPDE4 and HPDE4 can be inhibited by cilomilast (SB-207499) with IC50 of 100 nM and 120 nM.
CAS No.
153259-65-5
Molecular Weight
343.42
Purity
>99%
Storage
2 years at -20 centigrade
Targets
LPDE4, HPDE4
Molecular Formula
C20H25NO4
Chemical Name
4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid
Solubility
DSMO 69 mg/mL Water
In vitro
As a PDEIV inhibitor, Cilomilast inhibited TNFalpha release at concentrations >300 nM, but shows no inhibition to IL-6 release at any of the concentration in COPD lung macrophages. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes. Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity.
In vivo
Cilomilast inhibits human TNFalpha production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFalpha production, Cilomilast (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity.
Download
Download Datasheet